Wednesday 9 December at 9 am
Thanks to Alzheimer’s Disease imaging or fluid biomarkers, conclusions about an AD component can now be inferred in life. But does this mean that AD clinical research without biomarkers is invalid? What about pathological co-morbidities? Expert in this field Professor Ron Petersen of Mayo Clinic will discuss these issues in CHeBA’s upcoming Visiting Lecture Series event.